NASDAQ:NBIX Neurocrine Biosciences - NBIX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Neurocrine Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $110.03 +2.03 (+1.88%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$108.44▼$110.9050-Day Range$107.99▼$127.0652-Week Range$75.25▼$129.29Volume1.15 million shsAverage Volume872,826 shsMarket Capitalization$10.58 billionP/E Ratio193.04Dividend YieldN/APrice Target$122.24 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Neurocrine Biosciences MarketRank™ ForecastAnalyst RatingModerate Buy2.56 Rating ScoreUpside/Downside11.6% Upside$122.82 Price TargetShort InterestHealthy2.75% of Float Sold ShortDividend StrengthN/ASustainability-2.61Upright™ Environmental ScoreNews Sentiment0.37Based on 25 Articles This WeekInsider TradingSelling Shares$13.60 M Sold Last QuarterProj. Earnings Growth108.20%From $1.83 to $3.81 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.09 out of 5 starsMedical Sector457th out of 1,028 stocksBiological Products, Except Diagnostic Industry76th out of 168 stocks 2.3 Analyst's Opinion Consensus RatingNeurocrine Biosciences has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 10 buy ratings, 6 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $122.82, Neurocrine Biosciences has a forecasted upside of 11.6% from its current price of $110.03.Amount of Analyst CoverageNeurocrine Biosciences has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.75% of the float of Neurocrine Biosciences has been sold short.Short Interest Ratio / Days to CoverNeurocrine Biosciences has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Neurocrine Biosciences has recently increased by 15.11%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNeurocrine Biosciences does not currently pay a dividend.Dividend GrowthNeurocrine Biosciences does not have a long track record of dividend growth. Previous Next 2.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreNeurocrine Biosciences has received a 24.32% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Valbenazine", "Elagolix", and "Opicapone" products. See details.Environmental SustainabilityThe Environmental Impact score for Neurocrine Biosciences is -2.61. Previous Next 1.9 News and Social Media Coverage News SentimentNeurocrine Biosciences has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 25 news articles for Neurocrine Biosciences this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for NBIX on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 4 people have added Neurocrine Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Neurocrine Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $13,604,923.00 in company stock.Percentage Held by InsidersOnly 4.40% of the stock of Neurocrine Biosciences is held by insiders.Percentage Held by Institutions92.58% of the stock of Neurocrine Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Neurocrine Biosciences are expected to grow by 108.20% in the coming year, from $1.83 to $3.81 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Neurocrine Biosciences is 193.04, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 141.69.Price to Earnings Ratio vs. SectorThe P/E ratio of Neurocrine Biosciences is 193.04, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 138.85.Price to Book Value per Share RatioNeurocrine Biosciences has a P/B Ratio of 7.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Neurocrine Biosciences (NASDAQ:NBIX) StockNeurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.Read More Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Stock News HeadlinesJanuary 25, 2023 | marketbeat.comPliant Therapeutics Gaps 34% Higher: More Upside To Come? (NBIX)Pliant Therapeutics zoomed 34% higher and added to that gain in the next session.This followed good news about clinical trials for a lung-condition treatment.February 5, 2023 | americanbankingnews.comNeurocrine Biosciences (NBIX) to Release Quarterly Earnings on MondayFebruary 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…February 4, 2023 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Sells $141,104.34 in StockFebruary 4, 2023 | seekingalpha.comIngrezza's Potential To Dominate The Huntington's Chorea Market: A Boost For Neurocrine InvestorsFebruary 4, 2023 | americanbankingnews.comFY2023 EPS Estimates for Neurocrine Biosciences, Inc. Raised by Cantor Fitzgerald (NASDAQ:NBIX)February 3, 2023 | seekingalpha.comNeurocrine Biosciences Q4 2022 Earnings PreviewFebruary 3, 2023 | msn.comNeurocrine Biosciences Earnings PreviewFebruary 5, 2023 | Wall Street Watch Dogs (Ad)“Future Fuel” will unleash $11 trillion wave of wealthThe next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…February 3, 2023 | americanbankingnews.comInsider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells 2,707 Shares of StockFebruary 3, 2023 | americanbankingnews.comNeurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Eiry Roberts Sells 1,457 Shares of StockFebruary 3, 2023 | americanbankingnews.comResearch Analysts Set Expectations for Neurocrine Biosciences, Inc.'s FY2022 Earnings (NASDAQ:NBIX)January 31, 2023 | finance.yahoo.comCatalent (CTLT) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 ReleaseJanuary 27, 2023 | americanbankingnews.comWilliam Blair Research Analysts Lift Earnings Estimates for Neurocrine Biosciences, Inc. (NASDAQ:NBIX)January 25, 2023 | seekingalpha.comNeurocrine Biosciences: Stencil In These Important DatesJanuary 24, 2023 | seekingalpha.comNBIX Neurocrine Biosciences, Inc.January 17, 2023 | finance.yahoo.comNeurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2022 Financial ResultsJanuary 12, 2023 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: SAGE Therapeutics (SAGE) and Neurocrine (NBIX)January 11, 2023 | nasdaq.comNeurocrine, Voyager To Advance Multiple Gene Therapies For Neurological Diseases TreatmentJanuary 9, 2023 | bloomberg.comVoyager Could Get Up to $4.4 Billion in Neurocrine PartnershipJanuary 9, 2023 | bloomberg.comVoyager to Get as Much as $1.7 Billion in Neurocrine PartnershipJanuary 9, 2023 | finance.yahoo.comVoyager, Neurocrine sign new deal worth up to $4.2BJanuary 9, 2023 | msn.comVoyager jumps 29% on licensing deal with NeurocrineJanuary 6, 2023 | finance.yahoo.comDow Jones Rallies On December Jobs Report; Tesla Stock Dives To New Low On China Price CutsJanuary 3, 2023 | finance.yahoo.comNeurocrine Biosciences to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 28, 2022 | finance.yahoo.comDow Jones Futures Rise Ahead Of Economic Data; Tesla Stock Set To Rebound Amid Historic PlungeDecember 27, 2022 | finance.yahoo.comDow Jones Futures Rise Ahead Of Housing Data; Tesla Plunges On Reduced Production ScheduleSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NBIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Neurocrine Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address NBIX Company Calendar Last Earnings11/01/2021Today2/05/2023Next Earnings (Confirmed)2/06/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:NBIX CUSIP64125C10 CIK914475 Webwww.neurocrine.com Phone(858) 617-7600Fax858-617-7602Employees900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$122.82 High Stock Price Forecast$150.00 Low Stock Price Forecast$94.00 Forecasted Upside/Downside+11.1%Consensus RatingModerate Buy Rating Score (0-4)2.56 Research Coverage16 Analysts Profitability EPS (Most Recent Fiscal Year)$0.57 Trailing P/E Ratio193.04 Forward P/E Ratio60.13 P/E GrowthN/ANet Income$89.60 million Net Margins4.19% Pretax Margin5.92% Return on Equity4.06% Return on Assets2.78% Debt Debt-to-Equity RatioN/A Current Ratio2.49 Quick Ratio2.41 Sales & Book Value Annual Sales$1.13 billion Price / Sales9.33 Cash Flow$1.24 per share Price / Cash Flow88.61 Book Value$14.48 per share Price / Book7.60Miscellaneous Outstanding Shares96,130,000Free Float91,904,000Market Cap$10.58 billion OptionableOptionable Beta0.49 Key ExecutivesKevin Charles GormanChief Executive Officer & DirectorBill WilsonVice President-Information Technology & OperationsMatthew C. AbernethyChief Financial OfficerDimitri E. GrigoriadisChief Research OfficerEiry W. RobertsChief Medical OfficerKey CompetitorsRepligenNASDAQ:RGENHalozyme TherapeuticsNASDAQ:HALOExelixisNASDAQ:EXELSeagenNASDAQ:SGENBiogenNASDAQ:BIIBView All CompetitorsInsiders & InstitutionsBirchview Capital LPSold 1,000 shares on 2/3/2023Ownership: 0.088%Fisher Asset Management LLCSold 848 shares on 2/3/2023Ownership: 0.067%EFG Asset Management North America Corp.Sold 1,139 shares on 2/3/2023Ownership: 0.031%Securian Asset Management Inc.Bought 121 shares on 2/3/2023Ownership: 0.009%Larson Financial Group LLCBought 391 shares on 2/3/2023Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions NBIX Stock - Frequently Asked Questions Should I buy or sell Neurocrine Biosciences stock right now? 16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last twelve months. There are currently 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NBIX shares. View NBIX analyst ratings or view top-rated stocks. What is Neurocrine Biosciences' stock price forecast for 2023? 16 Wall Street analysts have issued 1-year target prices for Neurocrine Biosciences' shares. Their NBIX share price forecasts range from $94.00 to $150.00. On average, they anticipate the company's stock price to reach $122.82 in the next twelve months. This suggests a possible upside of 11.6% from the stock's current price. View analysts price targets for NBIX or view top-rated stocks among Wall Street analysts. How have NBIX shares performed in 2023? Neurocrine Biosciences' stock was trading at $119.44 at the beginning of 2023. Since then, NBIX stock has decreased by 7.9% and is now trading at $110.03. View the best growth stocks for 2023 here. Are investors shorting Neurocrine Biosciences? Neurocrine Biosciences saw a increase in short interest in January. As of January 15th, there was short interest totaling 2,590,000 shares, an increase of 15.1% from the December 31st total of 2,250,000 shares. Based on an average daily volume of 819,500 shares, the days-to-cover ratio is presently 3.2 days. Currently, 2.8% of the shares of the stock are sold short. View Neurocrine Biosciences' Short Interest. When is Neurocrine Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 6th 2023. View our NBIX earnings forecast. How can I listen to Neurocrine Biosciences' earnings call? Neurocrine Biosciences will be holding an earnings conference call on Monday, February 6th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Neurocrine Biosciences' earnings last quarter? Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its earnings results on Monday, November, 1st. The company reported $0.23 earnings per share for the quarter, missing the consensus estimate of $0.51 by $0.28. The business had revenue of $296 million for the quarter, compared to the consensus estimate of $297.02 million. Neurocrine Biosciences had a net margin of 4.19% and a trailing twelve-month return on equity of 4.06%. The business's revenue for the quarter was up 14.5% on a year-over-year basis. During the same period last year, the business earned ($0.62) earnings per share. What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO? 11 employees have rated Neurocrine Biosciences Chief Executive Officer Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among the company's employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Neurocrine Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Block (SQ) and Salesforce (CRM). What is Neurocrine Biosciences' stock symbol? Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX." Who are Neurocrine Biosciences' major shareholders? Neurocrine Biosciences' stock is owned by many different retail and institutional investors. Top institutional investors include Congress Asset Management Co. MA (0.95%), Allspring Global Investments Holdings LLC (0.52%), Tobam (0.30%), Sumitomo Mitsui Trust Holdings Inc. (0.30%), New York State Common Retirement Fund (0.24%) and Assenagon Asset Management S.A. (0.22%). Insiders that own company stock include Darin Lippoldt, David W Boyer, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy, Richard F Pops, Stephen A Sherwin and William H Rastetter. View institutional ownership trends. How do I buy shares of Neurocrine Biosciences? Shares of NBIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Neurocrine Biosciences' stock price today? One share of NBIX stock can currently be purchased for approximately $110.03. How much money does Neurocrine Biosciences make? Neurocrine Biosciences (NASDAQ:NBIX) has a market capitalization of $10.58 billion and generates $1.13 billion in revenue each year. The company earns $89.60 million in net income (profit) each year or $0.57 on an earnings per share basis. How many employees does Neurocrine Biosciences have? The company employs 900 workers across the globe. How can I contact Neurocrine Biosciences? Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The official website for the company is www.neurocrine.com. The company can be reached via phone at (858) 617-7600, via email at ir@neurocrine.com, or via fax at 858-617-7602. This page (NASDAQ:NBIX) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.